Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ASCO 2013 | Breast Cancer Program 1

ASCO 2013 Breast Cancer Journal 1

  • Neoadjuvant treatment in HER2
  • mTOR inhibition in HER2 positive BC
  • Endocrine resistance
  • This program is editorially independent and is financially made possible by

Related items

Congress news

ASCO 2018 Results of the TAILORx trial

Joseph Sparano, oncologist at Montefiore Medical Center, explains the results of the TAILORx trial, which he presented during the plenary session at ASCO 2018. This trial attempted to incorporate a gene expression test into clinic decision making for hormone receptor positive breast cancer.

Congress news

ASCO 2018 Rechallenge with bevacizumab in ovarian cancer

Dr. Sandro Pignata, oncologist and president of the Multicentre Italian Trial in Ovarian cancer (MITO) group, explains the results of the MITO 16b trial. This study evaluated whether the addition of bevacizumab to a platinum-based chemotherapy prolongs survival for recurrent ovarian cancer patients who had already received it during first line.

Congress news

ESMO 2017 in-depth: TONIC trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Marleen Kok, MD, PhD at The Netherlands Cancer Institute in Amsterdam, explains the design and first results of the TONIC trial. This adaptive phase II trial evaluated the response rate to nivolumab after induction treatment in patients with triple-negative breast cancer.